This site uses cookies to measure how you use the website so it can be updated and improved based on your needs and also uses cookies to help remember the notifications you’ve seen, like this one, so that we don’t show them to you again. If you could also tell us a little bit about yourself, this information will help us understand how we can support you better and make this site even easier for you to use and navigate.

Effect of immunotherapy with bapineuzumab on cerebrospinal fluid biomarker levels in patients with mild to moderate Alzheimer disease


Blennow, Kaj, Zetterberg, Henrik, Rinne, Juha O., Salloway, Stephen, Wei, Jenny, Black, Ronald, Grundman, Michael, Liu, Enchi


Archives Of Neurology, Volume: 69, No.: 8, Pages.: 1002-1010

Year of Publication



Background: Given the slow and variable clinical course of Alzheimer disease, very large and extended clinical trials are needed to identify a beneficial clinical effect of disease-modifying treatments. Therefore, biomarkers are essential to prove that an anti-β-amyloid (Aβ) drug candidate affects both Aβ metabolism and plaque load as well as downstream pathogenic mechanisms.; Objective: To evaluate the effect of the anti-Aβ monoclonal antibody bapineuzumab on cerebrospinal fluid (CSF) biomarkers reflecting Aβ homeostasis, neuronal degeneration, and tau-related pathology in patients with Alzheimer disease.; Design: Two phase 2, multicenter, randomized, double-blind, placebo-controlled clinical trials of 12-month duration.; Setting: Academic centers in the United States (Study 201) and England and Finland (Study 202).; Patients: Forty-six patients with mild to moderate Alzheimer disease.; Interventions: Patients received either placebo (n = 19) or bapineuzumab (n = 27) in 3 or 4 ascending dose groups.; Main Outcome Measures: Changes between end of study and baseline in the exploratory CSF biomarkers Aβ1-42, AβX-42, AβX-40; total tau (T-tau); and phosphorylated tau (P-tau).; Results: Within the bapineuzumab group, a decrease at end of study compared with baseline was found both for CSF T-tau (-72.3 pg/mL) and P-tau (-9.9 pg/mL). When comparing the treatment and placebo groups, this difference was statistically significant for P-tau (P = .03), while a similar trend for a decrease was found for T-tau (P = .09). No clear-cut differences were observed for CSF Aβ.; Conclusions: To our knowledge, this study is the first to show that passive Aβ immunotherapy with bapineuzumab results in decreases in CSF T-tau and P-tau, which may indicate downstream effects on the degenerative process. Cerebrospinal fluid biomarkers may be useful to monitor the effects of novel disease-modifying anti-Aβ drugs in clinical trials. TRIAL REGISTRATIONS Identifier: NCT00112073, EudraCT Identifier: 2004-004120-12, and Identifier: ISRCTN17517446.;


aged, alzheimer disease, amyloid betapeptides, antia, antibodies monoclonal humanized, antibody, bapineuzumab, biological markers, cerebrospinal, cerebrospinal fluid, cohort studies, doubleblind method, drug therapy, england, epidemiology, female, finland, fluid, humans, immunotherapy, levels, male, methods, middle aged, monoclonal, peptide fragments, tau proteins, therapeutic use, treatment outcome, united states

Countries of Study

Finland, UK, USA

Types of Dementia

Alzheimer’s Disease

Types of Study

Randomised Controlled Trial

Type of Outcomes


Type of Interventions

Pharmaceutical Interventions

Pharmaceutical Interventions